Under the terms of their 2006 collaboration agreement, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase II, will have primary responsibility for completing the global development and registration program.
In late May 2008, InterMune initiated a 14-day study of ITMN-191 in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.
Dan Welch, chairman, CEO and president of InterMune, said: “We look forward to the continued strong relationship with Roche as we together develop protease inhibitor therapies in combination with current standard of care and with other direct antiviral agents.”